LifeSci Investment Abstract
CymaBay Therapeutics (NasdaqCM: CBAY) is a clinical stage biopharmaceutical company
developing therapies for metabolic and orphan diseases. The Company’s lead product
candidate is arhalofenate, an anti-flare and serum uric acid (sUA) lowering drug for the
treatment of gout. Initial signs of efficacy have been shown in several Phase II trials. A
pivotal Phase III program is expected to launch in the first half of 2016 pending partnership
discussions. The Company’s is also developing MBX-8025 for the treatment of homozygous
familial hypercholesterolemia (HoFH) and primary biliary cirrhosis (PBC). Results from a
Phase I study in HoFH are expected in the fourth quarter of 2015 and CymaBay expects to
initiate a Phase II study in PBC in the first quarter of 2016.
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.
